Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | MAOB | P27338 | 1/20 | 0.65 |
| ▸ | NAMPT | P43490 | 7/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14726348 | 0.87 | CA2 (0.72) | RAB9APOLBNPC1MAOBNAMPT | |
| SCHEMBL14726350 | 0.86 | CA2 (0.74) | RAB9APOLBNPC1MAOBNAMPT | |
| SCHEMBL14726356 | 0.84 | ALDH1A1 (0.67) | NPC1NAMPTALDH1A1CA1CA2 | |
| SCHEMBL14726355 | 0.83 | CA2 (0.61) | NPC1NAMPTCA1CA2CA12 | |
| SCHEMBL26546719 | 0.82 | RAB9A (0.73) | RAB9APOLBNPC1MAOBNAMPT | |
| SCHEMBL14726349 | 0.80 | CA2 (0.62) | NAMPTCA1CA2CA12CA9 | |
| SCHEMBL16946645 | 0.80 | NPC1 (0.84) | RAB9APOLBNPC1MAOBNAMPT | |
| SCHEMBL7420189 | 0.79 | RAB9A (1.00) | RAB9APOLBNPC1MAOBNAMPT | |
| SCHEMBL8180564 | 0.79 | RAB9A (0.88) | RAB9APOLBNPC1MAOBNAMPT | |
| SCHEMBL20389029 | 0.79 | NAMPT (1.00) | RAB9APOLBNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053392-A1 | CARBONIC ANHYDRASE INHIBITORS | UNIVERSITETET I OSLO (NO) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053392-A1 | CARBONIC ANHYDRASE INHIBITORS | CA9, CA2, CA4 | RAB9A 196/4885POLB 4536/4885NPC1 2740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.